Subtopic Deep Dive
Smoking Cessation in Mental Illness
Research Guide
What is Smoking Cessation in Mental Illness?
Smoking cessation in mental illness focuses on tailored interventions to quit smoking among individuals with psychiatric disorders like schizophrenia, depression, and anxiety, addressing their disproportionately high smoking prevalence.
People with mental illness smoke at rates up to 70% of U.S. cigarettes consumed by nicotine-dependent and psychiatrically ill individuals (Grant et al., 2004, 1254 citations). Interventions include bupropion with nicotine patches yielding higher abstinence (Jorenby et al., 1999, 1601 citations). Cessation improves mental health outcomes comparably in psychiatric and non-psychiatric groups (Taylor et al., 2014, 997 citations). Over 10 key papers span guidelines and trials.
Why It Matters
Individuals with mental illness represent half of U.S. smokers, driving need for integrated cessation strategies to reduce health disparities (Grant et al., 2004). NIMH report outlines tobacco use patterns and treatments for schizophrenia, depression, and anxiety, emphasizing dual recovery barriers (Ziedonis et al., 2008). Meta-analysis shows quitting reduces depression and anxiety symptoms, supporting mental health benefits (Taylor et al., 2014). Guidelines recommend pharmacotherapy like bupropion and patches for sustained abstinence (Jorenby et al., 1999).
Key Research Challenges
High Relapse Rates
Psychiatric patients face elevated relapse due to nicotine dependence intertwined with symptom management (Grant et al., 2004). Abstinence symptoms like anxiety peak early, complicating recovery (Hughes, 2007). Integrated models struggle with adherence (Ziedonis et al., 2008).
Bidirectional Associations
Smoking links causally to depression and anxiety, with varied longitudinal evidence (Fluharty et al., 2016). Cessation worsens short-term mental health in some, delaying quits (Taylor et al., 2014). Distinguishing causality remains unresolved.
Tailored Intervention Efficacy
Standard NRT underperforms in psychiatric groups needing specialized pharmacotherapy (Jorenby et al., 1999). Guidelines lack precision for comorbidities like schizophrenia (Ziedonis et al., 2008). Evidence gaps persist for e-cigarettes and digital tools.
Essential Papers
A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation
Douglas E. Jorenby, Scott J. Leischow, Mitchell Nides et al. · 1999 · New England Journal of Medicine · 1.6K citations
Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch ...
A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update
⁎ · 2008 · American Journal of Preventive Medicine · 1.4K citations
Nicotine Dependence and Psychiatric Disorders in the United States
Bridget F. Grant, Deborah S. Hasin, S. Patricia Chou et al. · 2004 · Archives of General Psychiatry · 1.3K citations
Nicotine-dependent and psychiatrically ill individuals consume about 70% of all cigarettes smoked in the United States. The results of this study highlight the importance of focusing smoking cessat...
The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review
Meg Fluharty, Amy E. Taylor, Meryem Grabski et al. · 2016 · Nicotine & Tobacco Research · 1.2K citations
We systematically reviewed longitudinal studies on the association of different aspects of smoking behavior with depression and anxiety. The results varied considerably, with evidence for smoking b...
Electronic cigarettes for smoking cessation
Jamie Hartmann‐Boyce, Hayden McRobbie, Chris Bullen et al. · 2016 · Cochrane Database of Systematic Reviews · 1.0K citations
There is moderate-certainty evidence that ECs with nicotine increase quit rates compared to NRT and compared to ECs without nicotine. Evidence comparing nicotine EC with usual care/no treatment als...
Change in mental health after smoking cessation: systematic review and meta-analysis
Gemma Taylor, Ann McNeill, Alan Girling et al. · 2014 · BMJ · 997 citations
Smoking cessation is associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke. The effect size seems as large for tho...
Effects of abstinence from tobacco: Valid symptoms and time course
John R. Hughes · 2007 · Nicotine & Tobacco Research · 772 citations
This article updates a 1990 review of the effects of tobacco abstinence by reviewing (a) which symptoms are valid indicators of tobacco abstinence and (b) the time course of tobacco abstinence symp...
Reading Guide
Foundational Papers
Start with Grant et al. (2004) for U.S. prevalence linking nicotine dependence to psychiatric illness; Jorenby et al. (1999) for bupropion-patch trial benchmarks; Ziedonis et al. (2008) NIMH report for disorder-specific strategies.
Recent Advances
Taylor et al. (2014) meta-analysis on cessation's mental health benefits; Fluharty et al. (2016) systematic review of smoking-depression links; Hartmann-Boyce et al. (2016, 1014 citations) and (2018, 699 citations) on e-cigarettes and NRT.
Core Methods
Pharmacotherapies: sustained-release bupropion, nicotine patches (Jorenby et al., 1999); symptom assessment for abstinence validity (Hughes, 2007); meta-regression for mental health changes (Taylor et al., 2014); guideline updates (2008).
How PapersFlow Helps You Research Smoking Cessation in Mental Illness
Discover & Search
Research Agent uses searchPapers('smoking cessation schizophrenia depression') to find Ziedonis et al. (2008), then citationGraph reveals 728 citing papers on psychiatric interventions, and findSimilarPapers expands to Grant et al. (2004) for prevalence data.
Analyze & Verify
Analysis Agent applies readPaperContent on Taylor et al. (2014) to extract meta-analysis effect sizes, verifyResponse with CoVe checks claims against Jorenby et al. (1999) trial data, and runPythonAnalysis computes pooled abstinence rates with GRADE scoring high for mental health improvements.
Synthesize & Write
Synthesis Agent detects gaps in e-cigarette use for psychiatric smokers via contradiction flagging across Hartmann-Boyce et al. (2016) and Ziedonis et al. (2008); Writing Agent uses latexEditText for intervention review, latexSyncCitations integrates 10 papers, and latexCompile generates a polished manuscript with exportMermaid for relapse time-course diagrams.
Use Cases
"Meta-analyze depression improvement post-cessation in psychiatric patients"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-regression on Taylor 2014 + Fluharty 2016 effect sizes) → GRADE-verified summary statistics with confidence intervals.
"Draft LaTeX review on bupropion for schizophrenia smokers"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Jorenby 1999, Ziedonis 2008) → latexCompile → PDF with integrated figures.
"Find code for modeling smoking relapse in anxiety disorders"
Research Agent → paperExtractUrls (Hughes 2007) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (adapt simulation for time-course symptoms).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ on 'cessation mental illness') → DeepScan (7-step analysis with CoVe checkpoints on Grant 2004 and Taylor 2014) → structured report on interventions. Theorizer generates hypotheses on bidirectional smoking-depression links from Fluharty et al. (2016) + Hughes (2007), outputting testable models via exportMermaid.
Frequently Asked Questions
What defines smoking cessation in mental illness?
Tailored quitting strategies for psychiatric patients with high smoking rates, focusing on schizophrenia, depression, and anxiety via integrated pharmacotherapy and behavioral support (Ziedonis et al., 2008).
What are key methods?
Bupropion plus nicotine patch doubles abstinence over patch alone (Jorenby et al., 1999); NRT forms like gum and patches aid quits (Hartmann-Boyce et al., 2018); internet interventions show moderate efficacy (Taylor et al., 2017).
What are seminal papers?
Jorenby et al. (1999, 1601 citations) on bupropion efficacy; Grant et al. (2004, 1254 citations) on nicotine dependence in psychiatry; Taylor et al. (2014, 997 citations) meta-analysis of mental health gains.
What open problems exist?
Optimal e-cigarette role in psychiatric cessation (Hartmann-Boyce et al., 2016); long-term relapse prevention amid abstinence symptoms (Hughes, 2007); scaling integrated treatments for equity (Ziedonis et al., 2008).
Research Smoking Behavior and Cessation with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Smoking Cessation in Mental Illness with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Smoking Behavior and Cessation Research Guide